Vera 🍀 Hoffman Email & Phone Number

Cambridge, Ma, Us

Reveal is committed to transforming medical insight, improving human health, and enhancing environmental sustainability.Addressing the demand for advanced imaging, the company's Phase 2 clinical-stage manganese-based MRI contrast agent is designed to be a safe, gadolinium-free direct replacement for current MRI contrast agents (GBCAs). With over 50 million contrast-enhanced MRI scans per year, all GBCAs cause gadolinium accumulation in the brain and organs of every patient, and also drive rising levels of this toxic heavy metal in surface waters. Reveal’s pipeline includes first-in-class fibrogenesis imaging agents, with potential applications in diagnosing, monitoring, and enabling therapeutic development for fibrotic diseases such as heart failure, chronic liver disease, and certain cancers.+ Co-founder of Reveal with Peter Caravan and Eric Gale.+ Principal Investigator for Reveal's >$15 million in SBIR grants from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK). + Reveal has won additional support and awards from the Harvard Business School alumni New Venture Competition, MassChallenge, Massachusetts Life Sciences Center, MassVentures, and Endless Frontier Labs.

Bethesda, Md, Us

Principal Investigator on Reveal's Fast Track, Direct to Phase II, and Phase II B (Bridge) SBIR awards from the National Cancer Institute. NCI has cumulatively committed over $8M to support RVP-001 from pre-IND studies through clinical studies.

Bethesda, Md, Us

PI on Reveal's two Fast Track SBIRs and Commercialization Readiness Pilot Program SBIR awards from the NIDDK. NIDDK supported early development of RVP-001 and is funding pre-IND development of Reveal’s fibrogenesis imaging agent. NIDDK has cumulatively committed ~$5M to support Reveal’s research and development of innovative imaging agents.

Bethesda, Maryland, Us

PI on Reveal's Phase I and Phase II SBIR awards from the NHLBI, totaling over $2M.

Waltham, Massachusetts, Us

Reveal was awarded MassVentures START grants, advancing through the program's three stages and winning START.I, START II, and START III awards in successive years.

Waltham, Massachusetts, Us

Reveal was awarded the MLSC Milestone Achievement Program (MAP) to support execution of critical value-creating technical milestones.

Waltham, Massachusetts, Us

An inaugural MassNextGen awardee and grant winner.MassNextGen is a 5-year $1M initiative to provide support to women entrepreneurs in order to develop and promote a diverse generation of life science entrepreneurs.

Advisor to CEOs, founders, and investors. Focused on entrepreneurial companies at inflection points, bringing clarity to complex choices:+ Opportunity identification+ Company | context fit+ Product | market fit+ Defining strategy, aligning executionPassionate about designing and building companies positioned to shape the future and win enormous markets.

Innovation, intrepreneurship, and leadership development for Fortune 100 firms.Coached global teams of high potential Vice Presidents at one of the world’s largest financial companies. Guided creation of a fintech portfolio representing >$300M in potential annual revenues.

Boston, Ma, Us

Collaborated with Acquia founder Jay Batson and seed / lead investor Michael Skok to take Acquia from idea through inception and funding. Crafted Acquia's strategy, initial business plan, market analysis, positioning, and pitch for Seed and Series A financing. Acquia was acquired by Vista Equity Partners in a $1B deal.

Palo Alto, California, Us

Product strategy, product management, & product marketing for real time data analysis fintech.

Amsterdam, Nl

Transformed business models and industries through the application of innovative technology. Led engagements at the bleeding edge between global 1000 firms and startup technology companies.

Mba

Bsc Combined Hons, Mathematics & Chemistry